New drug TAS-205 aims to help kids with duchenne walk better

NCT ID NCT04587908

Ongoing Disease control Sponsor: Taiho Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether TAS-205, an oral drug, can improve movement and safety in people with Duchenne muscular dystrophy. It includes 104 participants, both those who can walk and those who cannot. The study compares TAS-205 to a placebo over 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAS-205 (oral drug)
What this could lead to: If successful, TAS-205 could offer a new treatment option to help slow muscle decline and improve mobility in people with Duchenne muscular dystrophy.
What could go wrong: This is still an experimental drug. Even in Phase 3, it may not prove effective or safe enough for approval. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENNE MUSCULAR DYSTROPHY

Contacts and locations

Show contact details

Locations

A site selected by Taiho Pharmaceutical Co., Ltd.

Aichi, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.

Fukuoka, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.

Hokkaido, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.

Osaka, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.

Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.